Login / Signup

Genome-wide association study of brain arteriolosclerosis.

Lincoln Mp ShadeYuriko KatsumataTimothy J HohmanKwangsik NhoAndrew J SaykinShubhabrata MukherjeeKevin L BoehmeJohn Sk KauweLindsay A FarrerGerard D SchellenbergJonathan L HainesRichard P MayeuxJulie A SchneiderPeter T NelsonDavid W Fardo
Published in: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2022)
Brain arteriolosclerosis (B-ASC) is characterized by pathologically altered brain parenchymal arterioles. B-ASC is associated with cognitive impairment and increased likelihood of clinical dementia. To date, no study has been conducted on genome-wide genetic risk of autopsy-proven B-ASC. We performed a genome-wide association study (GWAS) of the B-ASC phenotype using multiple independent aged neuropathologic cohorts. Included in the study were participants with B-ASC autopsy and genotype data available from the NACC, ROSMAP, ADNI, and ACT data sets. Initial Stage 1 GWAS ( n  = 3382) and Stage 2 mega-analysis ( n  = 4569) were performed using data from the two largest cohorts (NACC and ROSMAP). Replication of top variants and additional Stage 3 mega-analysis were performed incorporating two smaller cohorts (ADNI and ACT). Lead variants in the top two loci in the Stage 2 mega-analysis (rs7902929, p  =  1.8 × 10 - 7 ; rs2603462, p  =  4 × 10 - 7 ) were significant in the ADNI cohort (rs7902929, p  =  0.012 ; rs2603462, p = 0.012 ). The rs2603462 lead variant colocalized with ELOVL4 expression in the cerebellum (posterior probability = 90.1%). Suggestive associations were also found near SORCS1 and SORCS3 . We thus identified putative loci associated with B-ASC risk, but additional replication is needed.
Keyphrases
  • genome wide association study
  • genome wide
  • cognitive impairment
  • nlrp inflammasome
  • copy number
  • white matter
  • resting state
  • big data
  • mild cognitive impairment
  • cerebral ischemia
  • blood brain barrier
  • breast cancer risk